Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Long

Showing results (191-200 of 703) with videos related to

Pageof 71
Sort By:
Cancer Chemotherapy and Pharmacology|January 21, 2019
Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexiaHannah Yejin Kim, Janna K Duong, Maria Gonzalez, et al.
The American Journal of Surgical Pathology|December 17, 2013
Intrapatient homogeneity of BRAFV600E expression in melanomaAlexander M Menzies, Trina Lum, James S Wilmott, et al.
Melanoma Research|June 17, 2014
Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanomaSamantha E Bowyer, Aparna D Rao, Megan Lyle, et al.
European Journal of Cancer (Oxford, England : 1990)|June 13, 2024
Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti-PD-1 therapy: MASTERKEY-115Caroline Robert, Brian Gastman, Helen Gogas, et al.
Cancers|October 28, 2023
VEGF Inhibitors Improve Survival Outcomes in Patients with Liver Metastases across Cancer Types-A Meta-AnalysisJordan W Conway, Jorja Braden, Serigne N Lo, et al.
European Journal of Cancer (Oxford, England : 1990)|August 15, 2021
The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patientsAnne Zaremba, Alexander M M Eggermont, Caroline Robert, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 26, 2015
Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastasesHojabr Kakavand, Ricardo E Vilain, James S Wilmott, et al.
Pituitary|January 31, 2018
Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitisSunita M C De Sousa, Nisa Sheriff, Chau H Tran, et al.
Pathology|March 12, 2014
Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomasHojabr Kakavand, Oana Crainic, Trina Lum, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 4, 2015
Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanomaJames S Wilmott, Andrew J Colebatch, Hojabr Kakavand, et al.
Pageof 71

Showing results (191-200 of 703) with videos related to

Sort By:
Pageof 71
Cancer Chemotherapy and Pharmacology|January 21, 2019
Pharmacokinetic and cytokine profiles of melanoma patients with dabrafenib and trametinib-induced pyrexiaHannah Yejin Kim, Janna K Duong, Maria Gonzalez, et al.
The American Journal of Surgical Pathology|December 17, 2013
Intrapatient homogeneity of BRAFV600E expression in melanomaAlexander M Menzies, Trina Lum, James S Wilmott, et al.
Melanoma Research|June 17, 2014
Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanomaSamantha E Bowyer, Aparna D Rao, Megan Lyle, et al.
European Journal of Cancer (Oxford, England : 1990)|June 13, 2024
Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti-PD-1 therapy: MASTERKEY-115Caroline Robert, Brian Gastman, Helen Gogas, et al.
Cancers|October 28, 2023
VEGF Inhibitors Improve Survival Outcomes in Patients with Liver Metastases across Cancer Types-A Meta-AnalysisJordan W Conway, Jorja Braden, Serigne N Lo, et al.
European Journal of Cancer (Oxford, England : 1990)|August 15, 2021
The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patientsAnne Zaremba, Alexander M M Eggermont, Caroline Robert, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 26, 2015
Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastasesHojabr Kakavand, Ricardo E Vilain, James S Wilmott, et al.
Pituitary|January 31, 2018
Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitisSunita M C De Sousa, Nisa Sheriff, Chau H Tran, et al.
Pathology|March 12, 2014
Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomasHojabr Kakavand, Oana Crainic, Trina Lum, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 4, 2015
Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanomaJames S Wilmott, Andrew J Colebatch, Hojabr Kakavand, et al.
Pageof 71